Eisai has launched a new savings card for lorcaserin (Belviq), which has been approved by the FDA for chronic weight management, to increase the accessibility and affordability of the drug, according to a press release from the manufacturer.
The savings card allows eligible patients without commercial coverage to pay no more than $75.00 for each monthly lorcaserin prescription and those with commercial coverage to save money if their co-pay exceeds $50.00.
Patients can get the savings card through physician offices or pharmacies without activation or enrollment, according to information in the release. The card is also available for download at http://www.belviq.com/registrion and is good for purchase of one prescription for any 30-day period for up to 12 times per year.
The FDA has approved lorcaserin to be used in conjunction with diet and exercise for chronic weight management in adults with a BMI of 30 or greater (obese) or a BMI of 27 or greater (overweight) and at least one weight-related comorbidity, such as type 2 diabetes, hypertension or hyperlipidemia.
“It is our hope that the savings program will give individuals the opportunity to address their weight and, if appropriate, utilize prescription drug therapy as part of an overall health care plan to improve their weight and health,” Joe Nadglowski, president and CEO of the Obesity Action Coalition, said in the release.
This article originally appeared on Endocrinology Advisor